CPC A61K 33/38 (2013.01) [A61K 33/243 (2019.01); A61K 47/02 (2013.01); A61P 31/04 (2018.01)] | 20 Claims |
1. A medicinal nanocomposite, comprising:
80 to 99 wt. % carrier particles of a porous silicate material selected from the group consisting of mesoporous silica, silicalite, mesosilicalite, silver-incorporated silicalite, and silver-incorporated mesosilicalite, the carrier particles comprising a pore framework;
0.5 to 10 wt. % silver nanoparticles (Ag NPs) dispersed on the pore framework, the silver nanoparticles being distinct from silver present in the silver-incorporated silicalite and/or silver-incorporated mesosilicalite; and
0.5 to 10 wt. % of a platinum-containing pharmaceutical compound disposed on at least one surface selected from an interior pore surface of the carrier particles, an exterior surface of the carrier particles, and a surface of the silver nanoparticles,
wherein the medicinal nanocomposite releases less than 10 mol. % of the platinum-containing pharmaceutical compound after 60 to 84 hours at a pH of 4.5, based on an initial amount of the platinum-containing pharmaceutical compound present in the medicinal nanocomposite.
|